Elsevier

The Lancet

Volume 358, Issue 9278, 28 July 2001, Pages 295-296
The Lancet

Fast track — Research Letters
Effect of infliximab on sight-threatening panuveitis in Behcet's disease

https://doi.org/10.1016/S0140-6736(01)05497-6Get rights and content

Summary

Permanent loss of vision resulting from relapsing ocular inflammation occurs frequently in patients with Behcet's disease, despite intensive, chronic immunosuppressive therapy. Since tumour necrosis factor (TNF) might have an important pathogenetic role in Behcet's disease, we decided to give a single infusion of infliximab—a monoclonal antibody against TNF—to five patients with relapsing panuveitis, at the immediate onset of last relapse. Remission of ocular inflammation was evident within the first 24 h, and complete suppression was seen 7 days after treatment in all patients. No side-effects were noted. We suggest that infliximab is a rapid and effective new therapy for sight-threatening ocular inflammation in Behcet's disease.

References (5)

There are more references available in the full text version of this article.

Cited by (0)

View full text